75 related articles for article (PubMed ID: 12113128)
1. AEterna reports on its phase II trial of neovastat.
Expert Rev Anticancer Ther; 2001 Jun; 1(1):3-4. PubMed ID: 12113128
[No Abstract] [Full Text] [Related]
2. Neovastat, a naturally occurring multifunctional antiangiogenic drug, in phase III clinical trials.
Falardeau P; Champagne P; Poyet P; Hariton C; Dupont E
Semin Oncol; 2001 Dec; 28(6):620-5. PubMed ID: 11740820
[TBL] [Abstract][Full Text] [Related]
3. AE-941 (Neovastat): a novel multifunctional antiangiogenic compound.
Gingras D; Batist G; Béliveau R
Expert Rev Anticancer Ther; 2001 Oct; 1(3):341-7. PubMed ID: 12113101
[TBL] [Abstract][Full Text] [Related]
4. AE 941.
Drugs R D; 2004; 5(2):83-9. PubMed ID: 15293867
[TBL] [Abstract][Full Text] [Related]
5. Neovastat--a novel antiangiogenic drug for cancer therapy.
Gingras D; Boivin D; Deckers C; Gendron S; Barthomeuf C; Béliveau R
Anticancer Drugs; 2003 Feb; 14(2):91-6. PubMed ID: 12569294
[TBL] [Abstract][Full Text] [Related]
6. Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels.
Batist G; Patenaude F; Champagne P; Croteau D; Levinton C; Hariton C; Escudier B; Dupont E
Ann Oncol; 2002 Aug; 13(8):1259-63. PubMed ID: 12181250
[TBL] [Abstract][Full Text] [Related]
7. On the use of thalidomide as an antiangiogenic agent in the treatment of multiple myeloma.
Ribatti D; Vacca A
Ann Hematol; 2003 Apr; 82(4):262. PubMed ID: 12707735
[No Abstract] [Full Text] [Related]
8. [Thalidomide and others: new treatment for myeloma].
Malphettes M; Fermand JP
Rev Prat; 2003 Oct; 53(15):1633-5. PubMed ID: 14689905
[No Abstract] [Full Text] [Related]
9. [Multiple myeloma: the role of angiogenesis and therapeutic application of thalidomide].
Jurczyszyn A; Wolska-Smoleń T; Skotnicki AB
Przegl Lek; 2003; 60(8):542-7. PubMed ID: 14974349
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of thalidomide in the treatment of multiple myeloma.
Warzocha K; Kraj M; Pogłód R; Szpila T; Mendek-Czajkowska E; Chełstowska M; Tronina RH
Acta Pol Pharm; 2008; 65(6):771-4. PubMed ID: 19172865
[No Abstract] [Full Text] [Related]
11. Why not start with thalidomide?
Loprinzi C; Rajkumar SV
J Clin Oncol; 2003 Jun; 21(11):2211-4. PubMed ID: 12775748
[No Abstract] [Full Text] [Related]
12. Thalidomide and thrombosis.
Mehta P
Clin Adv Hematol Oncol; 2003 Aug; 1(8):464-5. PubMed ID: 16258433
[No Abstract] [Full Text] [Related]
13. Thalidomide: present and future in multiple myeloma.
Hussein MA
Expert Rev Anticancer Ther; 2005 Feb; 5(1):25-31. PubMed ID: 15757435
[TBL] [Abstract][Full Text] [Related]
14. Correspondence re: J. Lu et al., thalidomide metabolites in mice and patients with multiple myeloma. Clin. Cancer Res., 9: 1680-1688, 2003.
Zhou S
Clin Cancer Res; 2003 Nov; 9(14):5429; author reply 5429. PubMed ID: 14614031
[No Abstract] [Full Text] [Related]
15. Early changes in bone marrow morphology induced by thalidomide in refractory myeloma patients.
Corso A; Lorenzi A; Zappasodi P; Invernizzi R; Vanelli L; Lazzarino M
Haematologica; 2003 Aug; 88(8):958-60. PubMed ID: 12935985
[No Abstract] [Full Text] [Related]
16. Activation of tissue plasminogen activator gene transcription by Neovastat, a multifunctional antiangiogenic agent.
Gingras D; Nyalendo C; Di Tomasso G; Annabi B; Béliveau R
Biochem Biophys Res Commun; 2004 Jul; 320(1):205-12. PubMed ID: 15207722
[TBL] [Abstract][Full Text] [Related]
17. Correspondence re: K. Neben et al., high plasma basic fibroblast growth factor concentration is associated with response to thalidomide in progressive multiple myeloma. Clin. Cancer Res., 7: 2675-2681, 2001.
Go RS; Horstman AL
Clin Cancer Res; 2002 Aug; 8(8):2750; author reply 2751. PubMed ID: 12171909
[No Abstract] [Full Text] [Related]
18. Lenalidomide in multiple myeloma.
Richardson PG; Mitsiades C; Hideshima T; Anderson KC
Expert Rev Anticancer Ther; 2006 Aug; 6(8):1165-73. PubMed ID: 16925483
[TBL] [Abstract][Full Text] [Related]
19. [Thalidomide treatment in multiple myeloma].
Hattori Y
Rinsho Ketsueki; 2003 May; 44(5):302-12. PubMed ID: 12822404
[No Abstract] [Full Text] [Related]
20. Tumor angiogenesis in the bone marrow of multiple myeloma patients and its alteration by thalidomide treatment.
Du W; Hattori Y; Hashiguchi A; Kondoh K; Hozumi N; Ikeda Y; Sakamoto M; Hata J; Yamada T
Pathol Int; 2004 May; 54(5):285-94. PubMed ID: 15086832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
